Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Two years into a pandemic and with a death toll exceeding a reported 900,000 Americans, it is unacceptable that the FDA and NIAID are needlessly delaying a treatment for late-stage COVID-19 with a remarkable track record of success. This bureaucratic dragging of your feet appears in stark contrast to the expedited review of other treatments like remdesivir, Molnupiravir, Paxlovid and the COVID-19 vaccines. The FDA’s disparate review processes for different treatments that appears to favor large manufacturers is troubling.

https://roar-assets-auto.rbl.ms/documents/14130/2022-03-03%20Letter%20to%20FDA%20and%20NIAID%20re%20Right%20to%20Try.pdf